Pharmacokinetic/pharmacodynamic (PK/PD) relationships for the angiogenesis inhibitor ABT-510 in preclinical efficacy models

被引：0
|
作者：
Carr, R
Marsh, K
Schneider, A
Henkin, J
Wang, Y
Joseph, I
Khanna, C
Humerickhouse, R
机构：
来源：
EUROPEAN JOURNAL OF CANCER | 2002年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
250
引用
收藏
页码：S79 / S79
页数：1
相关论文
共 50 条
  • [1] Pharmacokinetics (PK) of the angiogenesis inhibitor ABT-510 in healthy subjects
    Karyekar, CS
    Carr, RA
    Andre, A
    Wang, Q
    Facey, I
    Marsh, K
    Daszkowski, D
    Humerickhouse, R
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 215S - 215S
  • [2] ABT-510 -: Oncolytic angiogenesis inhibitor
    Sorbera, LA
    Bayés, M
    DRUGS OF THE FUTURE, 2005, 30 (11) : 1081 - 1086
  • [3] Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer
    Hoekstra, R
    de Vos, FYFL
    Eskens, FALM
    Gietema, JA
    van der Gaast, A
    Groen, HJM
    Knight, RA
    Carr, RA
    Humerickhouse, RA
    Verweij, J
    de Vries, EGE
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) : 5188 - 5197
  • [4] Pharmacodynamic Parameters of Pharmacokinetic/Pharmacodynamic (PK/PD) Integration Models
    Zhang, Longfei
    Xie, Hongbing
    Wang, Yongqiang
    Wang, Hongjuan
    Hu, Jianhe
    Zhang, Gaiping
    FRONTIERS IN VETERINARY SCIENCE, 2022, 9
  • [5] Pharmacokinetic (PK) and pharmacodynamic (PD) relationships for intranasal corticosteroids (INCS)
    Daley-Yates, PT
    Richards, DH
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2001, 107 (02) : S313 - S313
  • [6] Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: Concepts and perspectives
    Derendorf, H
    Meibohm, B
    PHARMACEUTICAL RESEARCH, 1999, 16 (02) : 176 - 185
  • [7] Modeling of Pharmacokinetic/Pharmacodynamic (PK/PD) Relationships: Concepts and Perspectives
    Hartmut Derendorf
    Bernd Meibohm
    Pharmaceutical Research, 1999, 16 : 176 - 185
  • [8] HYDROMORPHONE BIOAVAILABILITY AND PHARMACOKINETIC-PHARMACODYNAMIC (PK-PD) RELATIONSHIPS
    INTURRISI, C
    PORTENOY, R
    STILLMAN, M
    COLBURN, W
    FOLEY, K
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 43 (02) : 162 - 162
  • [9] METHADONE INFUSIONS - PHARMACOKINETIC-PHARMACODYNAMIC (PK-PD) RELATIONSHIPS
    INTURRISI, C
    PORTENOY, R
    MAX, M
    COLBURN, W
    FOLEY, K
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1987, 41 (02) : 211 - 211
  • [10] Preclinical pharmacokinetic, pharmacodynamic and efficacy relationships of ALG-093702, a liver targeted PD-L1 small molecule inhibitor, in different in vivo models
    Roose, Heleen
    Zhang, Qingling
    Le, Kha
    Jekle, Andreas
    Rekstyte-Matiene, Kristina
    Stevens, Sarah
    Jaisinghani, Ruchika
    Liu, Cheng
    Chang, Sandra
    Stoycheva, Antitsa
    Blatt, Lawrence
    Beigelman, Leonid
    Symons, Julian
    Chanda, Sushmita
    Gonzalvez, Francois
    Wu, Tongfei
    JOURNAL OF HEPATOLOGY, 2023, 78 : S1030 - S1031
12345